Curcumin (turmeric) & Fatty liver disease (MASLD/MASH)

Written from the studies on PubMed, searched on 11 Nov 2026. Every number below comes from a study listed under Sources.

What people read

Posts online say that Curcumin (turmeric) helps with Fatty liver disease (MASLD/MASH).

What has been studied

• 28In people28 randomised trials
• 59In animals
• 6Only in the lab

What the studies found

!Curcumin (turmeric) has been tested in randomised trials in people with Fatty liver disease (MASLD/MASH).

We found 133 published papers on Curcumin (turmeric) and Fatty liver disease (MASLD/MASH). They were published between 2011 and 2027.

28 of them are studies in people (28 randomised trials), 32 are reviews, 59 are studies in animals and 6 are studies only in the lab. 1 paper was retracted.

The most important ones are listed under Sources.

Sources

1. The effect of curcumin-piperine supplementation on liver transient elastography and biochemical indices in patients with non-alcoholic fatty liver disease: A randomized controlled trial.2026 · Avicenna J Phytomed · Randomised trial
2. Efficacy of the nano curcumin supplementation on fibrosis, steatosis, inflammatory and metabolic status of liver fibrosis patients with non-alcoholic fatty liver origin: a study protocol for a double-blind randomized controlled trial.2026 · BMC Nutr · Randomised trial
3. Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.2025 · Sci Rep · Randomised trial
4. Curcumin for Inflammation Control in Individuals with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial.2025 · Nutrients · Randomised trial
5. Curcumin Supplementation as a Preventive Strategy Against Tamoxifen-Induced Nonalcoholic Fatty Liver Disease in ER+ Breast Cancer Patients: A Triple-Blind Randomized Placebo-Controlled Trial.2025 · J Diet Suppl · Randomised trial
6. Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.2025 · Hepatology · Randomised trial
7. Impaired postprandial GLP-2 response enhances endotoxemia, systemic inflammation, and kidney injury in metabolic dysfunction-associated steatohepatitis (MASH): effect of phospholipid curcumin meriva.2024 · Gut Microbes · Randomised trial
8. Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial.2024 · Am J Clin Nutr · Randomised trial
9. The effect of curcumin on anthropometric indices, blood pressure, lipid profiles, fasting blood glucose, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty livers.2023 · Front Nutr · Study in people
10. Efficacy of curcumin plus piperine co-supplementation in moderate-to-high hepatic steatosis: A double-blind, randomized, placebo-controlled clinical trial.2023 · Phytother Res · Study in people
11. Optimal dose window, formulation efficacy, and molecular mechanisms of curcumin in MASLD animal models: A systematic review and three-level meta-analysis.2027 · J Ethnopharmacol · Review
12. Effects of curcumin on anthropometric measurements in nonalcoholic fatty liver disease: An umbrella meta-analysis study.2026 · Medicine (Baltimore) · Review
13. Curcumin Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanism Exploration, Clinical Application Strategies, and Application Limitations Challenges.2026 · Phytother Res · Review
14. The therapeutic effect of curcumin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of animal studies.2025 · Front Pharmacol · Review
15. Synergistic Effects of Exercise and Nano-Curcumin Supplementation in Women with Lifestyle-Related Diseases: A Scoping Review.2025 · Nutrients · Review
16. Hepatoprotective and Fat-Accumulation-Reductive Effects of Curcumin on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).2025 · Curr Issues Mol Biol · Review
17. Curcumin alleviates metabolic dysfunction-associated steatotic liver disease via gut microbiota-dependent epigenetic alterations.2026 · Mol Biomed · In animals
18. Co-administration of empagliflozin and curcumin attenuates the development of MASLD by modulating lipid metabolism and adipose tissue browning in HFD-fed C57BL/6J mice.2026 · Life Sci · In animals
19. Curcumin ameliorates metabolic dysfunction-associated steatotic liver disease via targeting triokinase/FMN cyclase to regulate the expression of glycerol-3-phosphate acyltransferase 3: Integration of chemical proteomics and transcriptomics.2026 · Acta Pharm Sin B · In animals
20. Curcumin-Loaded Liposomes (hPLipo/Cur) with Liver-Targeting Properties for Efficient NAFLD Treatment by Alleviating Mitochondrial ROS-Mediated Ferroptosis via NRF2 Pathway.2026 · Mol Pharm · In animals
21. Curcumin alleviates non-alcoholic fatty liver disease by modulating inflammation, barrier function, and gut microbiota.2026 · Biochem Biophys Res Commun · In animals
22. Effects of Alcohol Extraction of Turmeric Decoction-Derived Exosome-Like Nanoparticles on Amelioration of Metabolic Dysfunction-Associated Steatotic Liver Disease.2026 · J Nutr · In animals
23. Curcumin from Turmeric Alleviates Lipid Metabolism: Network Pharmacology and Cellular Validation.2026 · Am J Chin Med · In the lab
24. Curcumin ameliorates high-glucose-induced lipid accumulation in HepG2 cells via AMPK activation and mTOR suppression.2025 · Biochem Biophys Res Commun · In the lab
25. Investigating the Effects of Curcumin on Lipid Metabolism and Cell Viability in HepG2 Cells: Potential Therapeutic Implications for Nonalcoholic Fatty Liver Disease.2025 · Drug Dev Res · In the lab
26. Curcumin and Andrographolide Co-Administration Safely Prevent Steatosis Induction and ROS Production in HepG2 Cell Line.2023 · Molecules · In the lab
27. The role of ADIPOQ methylation in curcumin-administrated experimental nonalcoholic fatty liver disease.2016 · J Dig Dis · RetractedRetracted
28. Curcumin in MASLD: a pleiotropic candidate in the era of targeted pharmacotherapy?2026 · Nat Prod Res · Other paper
29. Is curcumin the new kid on the block for the treatment of MASH?2025 · Hepatology · Other paper
30. Effect of nano-micelle curcumin on hepatic enzymes: A new treatment approach for non-alcoholic fatty liver disease (NAFLD).2023 · Avicenna J Phytomed · Other paper
31. Corrigendum to "Curcumin activation of nuclear factor E2-related factor 2 gene (Nrf2): Prophylactic and therapeutic effect in nonalcoholic steatohepatitis (NASH)" [Life Sci. 285 (2021) 119983].2022 · Life Sci · Other paper

Search PubMed yourself